Clinical trials
Metastatic Lung Carcinoma clinical trials
Below are recruiting metastatic lung carcinoma clinical trials, each written for real people, not researchers. We’re tracking 412 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07322341RecruitingPhase 2
Study of SX-682 with atezolizumab for advanced lung cancer
This trial tests a new drug combination (SX-682 plus atezolizumab) for people with advanced non-small cell lung cancer that has grown after standard treatments like immunotherapy and chemotherapy. It aims to see if the combination can help shrink or slow the cancer.
Seattle, WashingtonAges 18 years+ - NCT06482073Recruiting
Genetic testing for suspected lung cancer
This study looks at genetic changes in people with suspected or high-risk lung cancer. It aims to use those results to guide more personalized treatment decisions.
Rochester, MinnesotaAges 18 years+ - NCT07594626RecruitingPhase 1/Phase 2
BMS-986504 and Pemetrexed for Advanced Tumors With MTAP Loss
This trial tests a new drug (BMS-986504) combined with an existing chemotherapy (pemetrexed) for advanced solid cancers that have a specific genetic change called MTAP deletion. The trial aims to see if this combination can slow or stop tumor growth in patients whose cancer has progressed despite prior treatment.
Chicago, IllinoisAges 18 years+ - NCT07154290RecruitingPhase 2
Ubamatamab with or without REGN7075 for advanced lung cancer
This trial tests a new targeted therapy (ubamatamab) alone or with another drug (REGN7075) for people with advanced or metastatic non-small cell lung cancer that has gotten worse after standard treatment. It aims to see if targeting MUC16, a substance found on some cancer cells, can help control the cancer.
Goodyear, ArizonaAges 18 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT07123090RecruitingPhase 2
Triple Therapy for Advanced Kidney Cancer
This trial tests a combination of three drugs—sasanlimab (immunotherapy), palbociclib (targeted therapy), and axitinib (VEGF inhibitor)—for people with advanced kidney cancer who have not had prior treatment. It aims to see if this triple therapy is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT07017829RecruitingPhase 2
Combination therapy for STK11-mutant lung cancer
This trial tests a new drug (GT103) combined with the approved immunotherapy drug pembrolizumab for people with advanced lung cancer that has a specific genetic change (STK11). The goal is to see if adding GT103 helps control the cancer better than pembrolizumab alone.
Buffalo, New YorkAges 18 years+ - NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
Phoenix, ArizonaAges 18 years+ - NCT07144280RecruitingPhase 3
Study of a new drug vs docetaxel for advanced lung cancer
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
Alabaster, AlabamaAges 18 years+ - NCT07222566RecruitingPhase 3
New drug plus chemotherapy for advanced lung cancer
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
Bullhead City, ArizonaAges 18 years+ - NCT06518057RecruitingPhase 2
Sparing memory during brain radiation for leptomeningeal metastases
This trial tests a special type of radiation that avoids the memory center of the brain (the hippocampus) while treating cancer that has spread to the lining of the brain and spinal cord. It may help reduce side effects on thinking and memory for people with breast or lung cancer.
San Francisco, CaliforniaAges 18 years+ - NCT07619599RecruitingPhase 1
PET Scan to Track Lung Cancer Treatment Response
This study uses a special PET imaging scan to help doctors see how well pembrolizumab (an immunotherapy drug) is working against advanced non-small cell lung cancer. You'll receive the scan along with your regular pembrolizumab treatment and possible radiation therapy to help measure treatment response.
Duarte, CaliforniaAges 18 years+ - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Birmingham, AlabamaAges 18 years+ - NCT06014827RecruitingPhase 2
Targeted radiation and osimertinib for lung cancer with EGFR mutation
This trial tests a new approach for patients with advanced non-small cell lung cancer that has a specific EGFR mutation (Ex19del or L858R) and has started to grow again after at least six months on osimertinib. It combines two types of focused radiation with continued osimertinib to treat only the progressing spots while keeping the rest of the disease under control.
Duarte, CaliforniaAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Birmingham, AlabamaAges 18 years+ - NCT04181060RecruitingPhase 3
Osimertinib alone or with bevacizumab for EGFR-mutant lung cancer
This Phase 3 trial tests whether starting osimertinib with or without bevacizumab helps people with advanced EGFR-mutant lung cancer live longer and control the cancer better. Your EGFR mutation test result and past treatments are key to whether you can join.
Anchorage, AlaskaAges 18 years+ - NCT05098210RecruitingPhase 1
Personalized vaccine made from your tumor’s new immune targets
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
Seattle, WashingtonAges 18 years+ - NCT05705492RecruitingPhase 2
Olanzapine to help cancer-related weight and appetite loss
This Phase 2 trial tests whether olanzapine can help people with advanced cancer who are losing weight and not eating enough. It looks for improvements in appetite and weight while you receive your first-line palliative cancer treatment.
Portland, OregonAges 18 years+ - NCT03582124RecruitingPhase 1/Phase 2
Panitumumab dye to help find lung cancer during surgery
This trial tests a special dye drug (panitumumab-IRDye800) that may help surgeons better see lung cancer areas while operating. If it works, it could improve how well cancer tissue is found and removed during planned lung surgery.
Palo Alto, CaliforniaAges 19 years+ - NCT03786796RecruitingPhase 2
Olaparib for metastatic kidney cancer with specific DNA repair gene changes
This trial tests olaparib (a pill medicine) in people with kidney cancer that has spread and specific DNA “repair” gene mutations. The goal is to see whether this targeted treatment can slow the cancer or help it respond better after prior immunotherapy or blood-vessel–blocking therapy.
Baltimore, MarylandAges 18–120 - NCT03808337RecruitingPhase 2
SBRT radiation plus standard treatment for spread cancer
This trial looks at adding a focused radiation treatment called SBRT to standard care for cancers that have spread to a limited number of spots. It aims to control those spread-out tumors while still using the usual cancer treatment plan.
San Carlos, CaliforniaAges 18 years+ - NCT04151940Recruiting
PET/CT scan changes during chemo with immune therapy
This study looks at how PET/CT scan results change while you receive chemo plus an immune therapy (a PD-1/PD-L1 medicine) for stage IV lung cancer. The goal is to better understand what the scans mean during treatment, which may help guide care in the future.
Seattle, WashingtonAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Irvine, CaliforniaAges 12 years+ - NCT04693377Recruiting
Freezing tumor treatment plus targeted radiation for painful bone spread
This study tests whether combining a “freezing” procedure (cryoablation) with focused external radiation (SBRT) can reduce pain from bone metastases. It’s for people with certain cancers that have spread to bone and are having significant pain in a specific bone spot.
Houston, TexasAges 18 years+
Hear when a new Metastatic Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic lung carcinoma?
- Yes. Clin2 currently lists 412 recruiting metastatic lung carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic lung carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic lung carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.